With the disappearance of GLP-1 copies, patients with little options remain
The Futter provider, the art of Meds, no longer offers the Tirzepatide combination injection, but allows patients to place bulk orders before starting it. He went ahead and ordered a few months of vials but does not know what he wants to do when they escape. “I am very nervous about what happens,” he says. “I can get any drops I can get out of any vial, I can get a little longer.” (Since the release, Henry Medes offers new and current patients to order 40 weeks of Samglotide injection.
Jim Bertel, a 41-year-old who lives in Colorado and gives Tirzepatide credit to change his life, and was also able to store his GLP-1 hybrid drugs before stopping the sales provider. He is not sure what he wants to do later this month, and he spends his time cleaning Reddit and Facebook forums to find that Telehealth companies are still presenting medicines. “My plan is to do it month -by -month,” he says. “Jump from the provider to the provider.”
Jesse, 40, who sought to be specified only by his name, referred to a medical spa to receive composite drugs when he could not have access to his primary care insurance or provider. His provider initially wrote a copy of Wegovy, but he says it was “touch and go” that filled it. When he was unavailable, he was able to supplement with a composite version of Med SPA. But at the end of last year, Jesse received a letter from his insurance company that says he will no longer cover Vegu. His primary care provider then stopped writing weight loss drugs and said they were too painful. He returned to the Med SPA and recently obtained sophisticated Semaglutide, but the facilities said it could not be the case. He is now buying medicine from Mexico because he often travels to San Diego. “This is the doctors, you don’t need a copy and it’s cheaper,” he says. In Mexico, the Wegovy brand can be bought for about $ 200 per month.
The stained insurance coverage has helped the demand stimulus for GLP-1 composite products. Despite Wegovy and Zepbound’s approval for patients with body mass index 30 or more, and 27 or more for people with at least one weight-related disease, some insurance programs need higher BMI or additional criteria for cover-if they cover obesity drugs at all. “This is a major issue here and the fanatical diagnosis of obesity as a disease like us to do cancer and diabetes and more,” says Florence Halperin, an endocrinologist and chief medical director at Form, an online medical weight loss clinic.
Amanda Bonlo, the founder and CEO of the GLP-1 complex, a nonprofit organization that aims to help patients with these drugs, is not surprising about the patients who want patients. Bonello, who owns GLP-1 products, says that for many of the patients talking to them, the effect of these drugs is not just about their weight.
